Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
Adolescent
Adrenal Cortex Hormones
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Asian People
Child
Child, Preschool
Disease Progression
Disease Susceptibility
Female
Femur Head Necrosis
/ diagnosis
Humans
Incidence
Magnetic Resonance Imaging
Male
Patient Outcome Assessment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ complications
Public Health Surveillance
Risk Factors
Hip osteonecrosis
Magnetic resonance imaging screening
Pediatric leukemia/lymphoma
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
12
2020
accepted:
12
05
2021
revised:
12
05
2021
pubmed:
20
5
2021
medline:
10
8
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Osteonecrosis (ON), a long-term complication of acute lymphoblastic leukemia (ALL) treatment affects patients' quality of life. Although the incidence of any ON, including asymptomatic, was 21.7% among children with ALL in the U.S., the actual incidence and risk factors in Asia remain unknown. For over 11 years, we performed hip magnetic resonance imaging (MRI) screening to detect asymptomatic ON while initiating maintenance chemotherapy in newly diagnosed children with ALL. Overall, 164 of 175 patients underwent hip MRI screening. The incidence of symptomatic or any ON was 3.0% and 11.6%, respectively. Asymptomatic ON in patients < 10 and ≥ 10 years old was 4.0% and 35.9%, respectively (P < 0.001). In multivariate analysis, age ≥ 10 years was the only significant risk factor. Asymptomatic ON with necrosis of > 30% of the epiphyseal surface of the femoral head was detected in four patients (2.4%). All were ≥ 10 years. Three of them progressed to severe symptomatic ON. The incidence of any ON in Asia may be lower than that seen in the only screening study in the U.S. Future studies should clarify factors affecting such regional differences and develop an effective approach to avoid the progression of ON in children with ALL.
Identifiants
pubmed: 34008044
doi: 10.1007/s12185-021-03163-1
pii: 10.1007/s12185-021-03163-1
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-279Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.
doi: 10.1056/NEJMra1400972
Arico M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R, et al. Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica. 2003;88:747–53.
pubmed: 12857552
Ali N, Gohar S, Zaky I, Elghoneimy A, Youssef S, Sameer G, et al. Osteonecrosis in children with acute lymphoblastic leukemia: a report from Children’s Cancer Hospital Egypt (CCHE). Pediatr Blood Cancer. 2019;66:e27440.
doi: 10.1002/pbc.27440
Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL-BFM 95. Pediatr Blood Cancer. 2005;44:220–5.
doi: 10.1002/pbc.20244
Chen SH, Chang TY, Jaing TH, Lee MS, Wang CJ, Hung IJ, et al. Incidence, risk factors, and treatment outcome of symptomatic osteonecrosis in Taiwanese children with acute lymphoblastic leukemia: a retrospective cohort study of 245 patients in a single institution. Int J Hematol. 2015;102:41–7.
doi: 10.1007/s12185-015-1790-4
Heneghan MB, Rheingold SR, Li Y, Seif AE, Huang YS, McLeod L, et al. Treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:223-9 e2.
doi: 10.1016/j.clml.2015.12.009
Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzziello F, et al. Correspondence: osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian association of pediatric haemato-oncology (AIEOP). Blood Cancer J. 2018;8:115.
doi: 10.1038/s41408-018-0150-z
Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia. 2008;22:308–12.
doi: 10.1038/sj.leu.2405032
Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, et al. Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 study of Japan association of childhood leukemia study group. J Clin Oncol. 2018;36:900–7.
doi: 10.1200/JCO.2017.75.5066
Hyakuna N, Shimomura Y, Watanabe A, Taga T, Kikuta A, Matsushita T, et al. Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese childhood cancer and leukemia study group. J Pediatr Hematol Oncol. 2014;36:22–9.
doi: 10.1097/MPH.0000000000000039
Kaste SC, Pei D, Cheng C, Neel MD, Bowman WP, Ribeiro RC, et al. Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. J Clin Oncol. 2015;33:610–5.
doi: 10.1200/JCO.2014.57.5480
Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117:2340–7 (quiz 556).
doi: 10.1182/blood-2010-10-311969
Niinimaki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Paakko EL, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 2007;25:1498–504.
doi: 10.1200/JCO.2006.06.2539
Ribeiro RC, Fletcher BD, Kennedy W, Harrison PL, Neel MD, Kaste SC, et al. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia. 2001;15:891–7.
doi: 10.1038/sj.leu.2402139
te Winkel ML, Pieters R, Hop WC, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29:4143–50.
doi: 10.1200/JCO.2011.37.3217
Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.
doi: 10.1182/blood-2007-09-112920
Hasegawa D, Manabe A, Ohara A, Kikuchi A, Koh K, Kiyokawa N, et al. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study. Pediatr Blood Cancer. 2012;58:23–30.
doi: 10.1002/pbc.22965
Kato N, Sato K, Takimoto H, Sudo N. BMI for age references for Japanese children—based on the 2000 growth survey. Asia Pac J Public Health. 2008;20(Suppl):118–27.
pubmed: 19533870
Karimova EJ, Rai SN, Howard SC, Neel M, Britton L, Pui CH, et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol. 2007;25:1525–31.
doi: 10.1200/JCO.2006.07.9947
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Mogensen SS, Harila-Saari A, Makitie O, Myrberg IH, Niinimaki R, Vestli A, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27300.
doi: 10.1002/pbc.27300
Kunstreich M, Kummer S, Laws HJ, Borkhardt A, Kuhlen M. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016;101:1295–305.
doi: 10.3324/haematol.2016.147595
Kahn JM, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, et al. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05–001. Pediatr Blood Cancer. 2018. https://doi.org/10.1002/pbc.26871
doi: 10.1002/pbc.26871
pubmed: 29603618
pmcid: 5980713
Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22:3930–6.
doi: 10.1200/JCO.2004.11.020
Gagne V, Aubry-Morin A, Plesa M, Abaji R, Petrykey K, St-Onge P, et al. Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics. 2019;20:1189–97.
doi: 10.2217/pgs-2019-0087
Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126:1770–6.
doi: 10.1182/blood-2015-05-643601
Madadi F, Shamsian BS, Alavi S, Madadi F, Eajazi A, Aslani A. Avascular necrosis of the femoral head in children with acute lymphoblastic leukemia: a 4- to 9-year follow-up study. Orthopedics. 2011;34:e593–7.
doi: 10.3928/01477447-20110826-07
Yang W, Devidas M, Liu Y, Smith C, Dai Y, Winick N, et al. Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood. 2020;137:1550.
doi: 10.1182/blood.2020008471